The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) represents an increasing global health burden. Cellular senescence develops in response to cellular injury, leading not only to cell cycle arrest but also to alterations of the cellular phenotype and metabolic functions. In this review, we critically discuss the currently existing evidence for the involvement of cellular senescence in NAFLD in order to identify areas requiring further exploration. Hepatocyte senescence can be a central pathomechanism as it may foster intracellular fat accumulation, fibrosis and inflammation, also due to secretion of senescence-associated inflammatory mediators. However, in some non-parenchymal liver cell types, such as hepatic stellate cells, senescence may be beneficial by reducing the extracellular matrix deposition and thereby reducing fibrosis. Deciphering the detailed interaction between NAFLD and cellular senescence will be essential to discover novel therapeutic targets halting disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Disease progression in fatty liver disease. Obesity and metabolic disorders represent risk factors for NAFLD, which starts with fat accumulation in hepatocytes. Further disease progression is characterized by inflammation (NASH) and subsequent fibrogenesis leading to cirrhosis. NASH with and without cirrhosis bears the risk of developing hepatocellular carcinoma (HCC) [5,6,20].](https://figures.cochat.ai/paper-figures/23d01315a94e420ca4374747008d0181/the-potential-role-of-cellular-senescence-in-non-alcoholic-fatty-liver-disease-figure-1.jpg)
![Figure 2 Mechanisms of cellular senescence. Cellular senescence can have various triggers such as telomere shortening, DNA damage, oncogene activation and mitochondria-related factors such as reactive oxygen species (ROS) and mitochondrial DNA damage. Upon injury, the DNA damage response (DDR) mechanisms are activated and signal transduction through protein phosphorylation of ATM, ATR, CHKs stabilizes p53, thus inducing cell cycle arrest through RB. Senescence cells show high expression of p16 and p21 and high activity of SA-β-gal and secrete cytokines and chemoattractants via SASP (modified from Di Micco R et al. [30]).](https://figures.cochat.ai/paper-figures/ed7d67bcdfc94bc79bbe9dd77c47374a/the-potential-role-of-cellular-senescence-in-non-alcoholic-fatty-liver-disease-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, driven by signalling pathways such as NOTCH1, SASP cells contribute to a pro-inflammatory microenvironment by secreting inflammatory cytokines, growth factors and matrix-degrading enzymes which have been implicated in the progression of NASH.45,46”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“Key responses of hepatocytes to metabolic injury include the activation of inflammatory and pro-apoptotic signalling, e.g. via tumour necrosis factor (TNF)α and NF-κB,3 favouring hepatocyte cell death pathways and/or senescence.16,17”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 6×
“This culminates into a vicious cycle of accelerated fat accumulation, cell death and HCC development through ER stress, ROS activation and NAFLD progression [65].”
BackgroundInfluentialEslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · cited 1×
“Recently, a new term called metabolic-dysfunctionassociated fatty liver disease (MAFLD) was introduced to describe more appropriately the spectrum of pathomechanistic changes and to prevent the simple dichotomous classification to steatohepatitis and non-steatohepatitis [8].”
BackgroundMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 2×
“Hepatocyte fat accumulation and inflammation are the main drivers of disease progression [12,13] and the subsequent hepatocellular injury is characterized by alterations of the cellular function.”
BackgroundCellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“However, some studies reported that NAFLD develops in 10–20% of non-obese people, so-called lean NAFLD [4,7].”
BackgroundInflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · cited 1×
“Hepatocyte fat accumulation and inflammation are the main drivers of disease progression [12,13] and the subsequent hepatocellular injury is characterized by alterations of the cellular function.”
BackgroundInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399 · cited 1×
“It is believed that 7–30% of those with NAFLD fulfill criteria for NASH [3,4].”
BackgroundCellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277 · cited 4×
“Upon injury, the DDR forms a complex of DNA response factors, including phosphorylated H2AX (γH2AX), MDC1, 53BP1 and activated ataxia telangiectasia mutated (ATM), creating foci surrounding the damaged areas [30].”
BackgroundInfluentialPersistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Cited by
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationUnderstanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Self-citationThe Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
“In NASH, a proinflammatory hepatic microenvironment stimulates fibrogenic processes leading to liver fibrosis and, eventually, cirrhosis.(3) The only curative therapy for end-stage liver disease and the early stages of hepatocellular carcinoma is liver transplantation.”
BackgroundSelf-citationZhang, C.-Y., Tan, X., Yang, H., Jin, L., Hong, J., Zhou, Y., & Huang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158267 · Cited by 98
“Some studies have proposed that hepatocyte senescence may be a central pathological mechanism that can promote intracellular fat accumulation, fibrosis and inflammation, and secretory inflammatory mediators related to senescence [37].”
Background
Metadata
- Authors
- Engelmann, C., & Tacke, F.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Engelmann, Cornelius
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-01-07
- Volume
- 23
- Issue
- 2
- Pages
- 652
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8775400
- OpenAlex
- W4205372104
- Cited by
- 61
- References
- 90
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 14 · 2023: 10 · 2022: 12
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
- Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- CSL Behring
- Berlin Institute of Health
- Allergan
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- cellular senescence, non-alcoholic fatty liver disease, hepatocyte senescence, hepatic stellate cells, liver fibrosis, senescence-associated inflammation, extracellular matrix deposition, therapeutic target
- MeSH terms
- Extracellular Matrix, Humans, Cellular Senescence, Disease Progression, Hepatocytes, Hepatic Stellate Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.